AE Wealth Management LLC Raises Stock Holdings in Abbott Laboratories $ABT

AE Wealth Management LLC boosted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 20.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 65,504 shares of the healthcare product maker’s stock after acquiring an additional 11,264 shares during the quarter. AE Wealth Management LLC’s holdings in Abbott Laboratories were worth $8,774,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Private Wealth Asset Management LLC boosted its stake in shares of Abbott Laboratories by 14.1% during the third quarter. Private Wealth Asset Management LLC now owns 12,955 shares of the healthcare product maker’s stock valued at $1,735,000 after purchasing an additional 1,600 shares during the period. Great Lakes Advisors LLC lifted its holdings in Abbott Laboratories by 3.7% during the 3rd quarter. Great Lakes Advisors LLC now owns 1,342,628 shares of the healthcare product maker’s stock valued at $179,832,000 after buying an additional 48,450 shares in the last quarter. Fidelis Capital Partners LLC boosted its position in Abbott Laboratories by 30.8% in the 3rd quarter. Fidelis Capital Partners LLC now owns 26,530 shares of the healthcare product maker’s stock valued at $3,553,000 after buying an additional 6,240 shares during the period. Flossbach Von Storch SE grew its stake in Abbott Laboratories by 2.9% in the 3rd quarter. Flossbach Von Storch SE now owns 6,609,983 shares of the healthcare product maker’s stock worth $885,341,000 after acquiring an additional 187,113 shares in the last quarter. Finally, Folger Nolan Fleming Douglas Capital Management Inc. increased its position in shares of Abbott Laboratories by 2.2% during the third quarter. Folger Nolan Fleming Douglas Capital Management Inc. now owns 97,890 shares of the healthcare product maker’s stock worth $13,111,000 after acquiring an additional 2,094 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on ABT. Citigroup dropped their price objective on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Royal Bank Of Canada dropped their price target on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Argus cut their price target on Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday. Barclays upped their price objective on shares of Abbott Laboratories from $162.00 to $169.00 and gave the stock an “overweight” rating in a research note on Monday, January 5th. Finally, Jefferies Financial Group raised their target price on shares of Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a research report on Thursday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $140.75.

Abbott Laboratories Price Performance

Shares of ABT opened at $109.31 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The firm has a 50-day simple moving average of $122.77 and a two-hundred day simple moving average of $127.49. Abbott Laboratories has a 1-year low of $105.27 and a 1-year high of $141.23. The stock has a market cap of $190.08 billion, a PE ratio of 29.39, a P/E/G ratio of 1.69 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Thursday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.